menu search

MAIA / MAIA Biotechnology: Progress In The THIO-101 Trial Sets Up A 2023 Catalyst

MAIA Biotechnology: Progress In The THIO-101 Trial Sets Up A 2023 Catalyst
MAIA's THIO-101 trial of 6-thio-2-deoxyguanosine in non-small cell lung cancer had enrolled 29 patients as of a June 20 update from the company. The first two patients in the trial have achieved continued survival at 10 and 11 months following the start of treatment. MAIA has enough cash to make it to an update from the trial, but another cash raise could be ahead. Read More
Posted: Jul 1 2023, 02:41
Author Name: Seeking Alpha
Views: 111010

MAIA News  

MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023

By Business Wire
October 19, 2023

MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at ESMO Congress 202 more_horizontal

MAIA Biotechnology: Progress In The THIO-101 Trial Sets Up A 2023 Catalyst

By Seeking Alpha
July 1, 2023

MAIA Biotechnology: Progress In The THIO-101 Trial Sets Up A 2023 Catalyst

MAIA's THIO-101 trial of 6-thio-2-deoxyguanosine in non-small cell lung cancer had enrolled 29 patients as of a June 20 update from the company. The f more_horizontal

MAIA Biotechnology (MAIA) Up on Positive Data From NSCLC Study

By Zacks Investment Research
April 12, 2023

MAIA Biotechnology (MAIA) Up on Positive Data From NSCLC Study

MAIA Biotechnology (MAIA) gains on encouraging data on lead candidate from Part A of its mid-stage study in advanced non-small cell lung cancer. more_horizontal


Search within

Pages Search Results: